Distinct immune evasion in APOBEC‐enriched, HPV‐negative HNSCC
暂无分享,去创建一个
S. Fröhling | B. Obermayer | W. Weichert | A. Stenzinger | F. Klauschen | D. Beule | I. Tinhofer | D. Rieke | D. Treue | H. Glimm | K. Schulze-Osthoff | T. Kindler | U. Keilholz | C. Brandts | S. Ochsenreither | K. Klinghammer | Clemens Messerschmidt
[1] F. Jamali,et al. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. , 2002, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[2] T. Chan,et al. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. , 2019, Oral oncology.
[3] S. Fröhling,et al. Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC , 2019, bioRxiv.
[4] M. Stratton,et al. Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis , 2019, Cell.
[5] M. Kloor,et al. Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden , 2018, Oncoimmunology.
[6] J. Lunceford,et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy , 2018, Science.
[7] R. Greil,et al. KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] Jonathan C. Cheng,et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 , 2018, British Journal of Cancer.
[9] G. Getz,et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors , 2018, Nature Genetics.
[10] M. Jia,et al. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer , 2018, Oncogene.
[11] Paul Hoffman,et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.
[12] C. Swanton,et al. Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] Chi-Ching Lee,et al. mSignatureDB: a database for deciphering mutational signatures in human cancers , 2017, Nucleic Acids Res..
[14] Shawn M. Gillespie,et al. Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer , 2017, Cell.
[15] Feng Zhang,et al. Identification of essential genes for cancer immunotherapy , 2017, Nature.
[16] S. Lantuejoul,et al. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] J. Lunceford,et al. IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.
[18] J. Meeks,et al. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response , 2017, bioRxiv.
[19] Rob Patro,et al. Salmon provides fast and bias-aware quantification of transcript expression , 2017, Nature Methods.
[20] Pornpimol Charoentong,et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.
[21] D. Rieke,et al. Targeted Therapy of Head and Neck Cancer , 2016, Oncology Research and Treatment.
[22] K. Harrington,et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.
[23] J. Lunceford,et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.
[24] G. Freeman,et al. Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma , 2016, Scientific Reports.
[25] J. Lunceford,et al. Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). , 2016 .
[26] Antoni Ribas,et al. The “cancer immunogram” , 2016, Science.
[27] A. Sieuwerts,et al. APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma , 2016, Clinical Cancer Research.
[28] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[29] C. Swanton,et al. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. , 2015, Cancer discovery.
[30] Nicolai J. Birkbak,et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution , 2015, Science Translational Medicine.
[31] Steven J. M. Jones,et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.
[32] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[33] Kevin P. White,et al. Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes , 2014, Clinical Cancer Research.
[34] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[35] S. Henderson,et al. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. , 2014, Cell reports.
[36] Damian Smedley,et al. Jannovar: A Java Library for Exome Annotation , 2014, Human mutation.
[37] A. Furano,et al. Repair of naturally occurring mismatches can induce mutations in flanking DNA , 2014, eLife.
[38] Steven J. M. Jones,et al. Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.
[39] T. Samuelsson,et al. The landscape of viral expression and host gene fusion and adaptation in human cancer , 2013, Nature Communications.
[40] Steven A. Roberts,et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.
[41] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[42] N. A. Temiz,et al. Evidence for APOBEC3B mutagenesis in multiple human cancers , 2013, Nature Genetics.
[43] M. Stratton,et al. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis , 2013, eLife.
[44] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[45] Justin Guinney,et al. GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.
[46] Steven J. M. Jones,et al. Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.
[47] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[48] J. Paramio,et al. Molecular Signature of HPV-Induced Carcinogenesis: pRb, p53 and Gene Expression Profiling , 2009, Current genomics.